Journal
JOURNAL OF CLINICAL PATHOLOGY
Volume 64, Issue 8, Pages 649-653Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jcp.2011.089847
Keywords
-
Categories
Funding
- Roche Products Ltd, Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire
Ask authors/readers for more resources
These guidelines supplement existing guidelines on HER2 testing by immunohistochemistry and in-situ hybridisation(ISH) methods in the UK. They provide a specific focus on aspects of guidance relevant to HER2 ISH testing methods, both fluorescent and chromogenic. They are formulated to give advice on methodology, interpretation and quality control for ISH-based testing of HER2 status in common tumour types, including both breast and gastric tumours. The aim is to ensure that all ISH-based testing is accurate, reliable and timely.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available